Melanoma

Medical Care Technologies (OTC PINK:MDCE) Advances AI Research to Help Identify Early Health Risks in Skin Cancer, Vision, Wound Care, and Mental Wellness

MESA, ARIZONA / ACCESS Newswire / October 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a developer of artificial…

2 months ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…

2 months ago

Medical Care Technologies (OTC Pink:MDCE) Outlines Regulatory Roadmap: Dividing AI Health Platform Into Clinical and Consumer Divisions

MESA, ARIZONA / ACCESS Newswire / October 7, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), an emerging innovator in…

2 months ago

Children’s Hospital of Philadelphia Pediatric Cancer Researcher Receives Prestigious Grant for Advancing Rare Tumor Studies

 Grant supports CHOP's dedication to understanding and treating rare tumors  PHILADELPHIA, Sept. 29, 2025 /PRNewswire/ -- Children's Hospital of Philadelphia…

2 months ago

ELEPHAS BIOSCIENCES WELCOMES DR. JEROME GALON TO THE COMPANY’S EXPANDING SCIENTIFIC ADVISORY BOARD

Internationally recognized expert joins to support the organization's commercialization strategy MADISON, Wis., Sept. 25, 2025 /PRNewswire/ -- Elephas Biosciences Corporation…

2 months ago

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is…

2 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”),…

2 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell…

2 months ago

Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting

WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology…

2 months ago